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Hospital Resources 
for Pandemic 
Infl uenza
To the Editor: In their November 
2007 article, Pandemic Infl uenza and 
Hospital Resources, Nap et al. evalu-
ated hospital resources for pandemic 
infl uenza in the northern part of the 
Netherlands (1). Their results can be 
compared with those that I have de-
scribed for the combined suburban 
communities of Roswell and Alpharet-
ta, Georgia, USA (2). The Netherlands 
evaluation assumed that antiviral 
drugs will be available and will reduce 
hospitalizations by 50% and deaths by 
30%. In view of the uncertainty of ef-
fective antiviral drugs and timeliness 
of vaccines, I did not estimate their 
effects. Nevertheless, several issues 
warrant comparison.
The plan for the Netherlands has 
no provisions for urgent care, i.e., par-
enteral fl uids or antimicrobial drugs 
that are administered to ambulatory 
patients who are not hospitalized. 
Nap et al. may not perceive a need for 
enough beds to handle surge capacity. 
Allowing for 30% of beds to be used 
for patients with conditions other than 
infl uenza, they report a maximum 
availability of 232 beds per 100,000 
population for pandemic infl uenza pa-
tients, and they estimate use of 72 beds 
per 100,000 in the pandemic model. In 
contrast, a maximum of 47 beds per 
100,000 are available in Roswell/Al-
pharetta. Availability of beds in inten-
sive care units, however, is identical 
for both regions, at 8 beds per 100,000 
population.
The Netherlands plan calls for 
intensifi ed treatment evaluation in 48 
hours to withdraw care from patients 
who have little chance for recovery. 
Because most patients can be expect-
ed to have pneumonia and 2-organ 
failure (on average), a 50% mortality 
rate can be expected. In US hospitals, 
withdrawing care is diffi cult, even if 
mortality rates are expected to be 75% 
or 90% during acute illness with organ 
failure.
The pandemic infl uenza resource 
evaluation from the northern part of 
the  Netherlands provides a useful con-
trast with at least 1 US hospital. The 
dramatic difference in bed availabil-
ity highlights the potential challenges 
involved in local planning. The surge 
capacity limits in Roswell/Alpharetta 
led us to consider an alternative infu-
sion center to provide care during an 
infl uenza pandemic.
Michael P. Dailey*
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Multidrug-Resistant 
Acinetobacter 
baumannii 
Osteomyelitis 
from Iraq
To the Editor: Acinetobacter 
baumannii identifi ed in military set-
tings is commonly multidrug resistant 
(MDR) (1–3). Tigecycline displays A. 
baumannii activity, but clinical ex-
perience is limited. We report a case 
of probable osteomyelitis caused by 
MDR A. baumannii and treated with 
tigecycline.
A 55-year-old man was transport-
ing soldiers in Iraq when he sustained 
a grenade injury, in which material 
entered his anterior thigh and created 
a large posterolateral hip exit wound 
and an open left subtrochanteric femur 
fracture. He was fl own to Germany; 
his wound was debrided, and the frac-
ture was stabilized with an external 
fi xator along with pins to his ilium and 
proximal and distal femur. A wound 
vacuum covered the exposed bones 
within the large soft tissue defect. He 
was stable upon transfer to our hospi-
tal 14 days after the injury; leukocyte 
count was 16,000/μL (reference range 
4.5–11,000/μL), and erythrocyte sedi-
mentation rate (ESR) was 44 mm/h 
(reference range 0–19 mm/h); blood 
cultures were not obtained. Plain radio-
graphs showed an open femur fracture 
with gas in the soft tissue, shrapnel, 
and a gross deformity of the left iliac 
wing. 111Indium-labeled leukocyte im-
aging confi rmed increased activity in 
the left acetabulum, femoral neck, and 
surrounding soft tissue. Two days after 
his arrival, the external fi xator (except 
for 1 pin in the distal shaft and 1 in the 
proximal femur) was removed, and an 
open reduction and internal fi xation 
(ORIF) of the femur was performed. A 
cephalomedullary femoral rod and hip 
screw and 60 tobramycin-impregnated 
beads were placed into the hip joint; 
a wound vacuum was placed over the 
defect. A deep sample of the iliac wing 
was obtained, ground into a homoge-
nate, placed aseptically on media, and 
observed for microbial growth; both 
coagulase-negative Staphylococcus 
and gram-negative rods grew in 1 cul-
ture. Both were considered pathogens 
of probable osteomyelitis based on 
exposed periosteum. Treatment with 
vancomycin plus ciprofl oxacin was 
begun. After the gram-negative rods 
were identifi ed as MDR A. bauman-
nii, tigecycline (MIC 1.5) was sub-
stituted for ciprofl oxacin (MIC>2). 
A. baumannii was susceptible to to-
bramycin (MIC<2), intermediate to 
imipenem (MIC 8), and resistant to 
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all other agents tested (Microscan, 
Dade Behring Company, Deerfi eld, 
IL, USA). Tigecycline susceptibility 
was performed by Etest (AB Biodisk, 
Solna, Sweden); breakpoints were 
inferred from available literature for 
Enterobacteriaceae (<2.0 is suscepti-
ble) as no current Clinical Laboratory 
Standards Institute breakpoints are 
established (4). Susceptibility testing 
for Staphylococcus spp. was not per-
formed; tigecycline’s role in treating 
the staphylococci in this setting was 
not determined because vancomycin 
was also used.
Postoperatively, leukocyte count 
returned to normal, wound drainage 
decreased, and a computed tomo-
graphic scan showed appropriate fe-
mur alignment with progressive het-
erotopic bone in the ilium. The patient 
was transferred to our rehabilitation 
facility and continued on vancomycin 
and tigecycline. Two weeks after the 
ORIF (hospital day 38), the wound 
vacuum was removed, a split-thick-
ness skin graft was placed, and the 
patient was discharged. He returned 
to our infectious diseases clinic 2 
weeks later; ESR was 12; tigecycline 
and vancomycin were stopped after 
43 days. The probable osteomyelitis 
of the femur and ilium was resolved 
by standard clinical and radiologic pa-
rameters.
Tigecycline has displayed activ-
ity against many MDR pathogens, 
including A. baumannii in vitro (4), 
although recent investigations have 
demonstrated resistance and inconsis-
tent susceptibility patterns (5). Clini-
cal management of A. baumannii bone 
infections in humans has not been well 
established. In an experimental animal 
model of methicillin-resistant S. aure-
us, tigecycline showed adequate bone 
concentration with microbial clearance 
in 90% and 100% of patients who re-
ceived tigecycline and tigecycline plus 
rifampin, respectively (6). This sug-
gests that tigecycline may have also 
been useful for the coagulase-negative 
staphylococci identifi ed in this patient 
and could have been considered as the 
sole treatment agent.
Tigecycline concentration in bone 
was also evaluated in an experimen-
tal rat model and a single-dose human 
study (7,8). The rat model showed an 
area under the curve in bone ≈250× 
higher than plasma (7). The investi-
gation in humans could not duplicate 
these results; the discrepancy was at-
tributed to either tight binding of ti-
gecycline to bone or poor extraction 
methods (8). The testing method used 
in previous animal models was re-
cently adapted for human use and has 
suggested increased sensitivity (9). 
An assessment of human bone con-
centrations after multiple tigecycline 
doses may be necessary to determine 
the potential role in osteomyelitis 
management.
Tobramycin bone and surround-
ing tissue concentrations have been 
demonstrated after tobramycin-im-
pregnated beads were placed in ani-
mals and humans with open fractures 
or chronic osteomyelitis (10). The role 
of tobramycin beads is not established 
for osteomyelitis, but use is common. 
Their contribution to this patient’s 
outcome is diffi cult to assess because 
A. baumannii was also susceptible to 
tobramycin.
Cases of A. baumannii osteomy-
elitis have been documented recently, 
but isolates were susceptible to other 
agents; none were treated with tigecy-
cline (3). The role of tigecycline for 
osteomyelitis with MDR A. bauman-
nii requires further study.
J.E.M. received research funding 
from Wyeth to perform synergy testing 
with tigecycline. 
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Dengue Virus, 
Nepal
To the Editor: Dengue virus be-
longs to the genus Flavivirus, family 
Flaviviridae. It has 4 serotypes: den-
gue virus type 1 (DENV-1), dengue 
virus type 2 (DENV-2), dengue virus 
type 3 (DENV-3), and dengue virus 
type 4 (DENV-4). Dengue virus is 
maintained in a cycle between humans 
and Aedes aegypti, domestic day-bit-
ing mosquitoes. Dengue virus induces 
clinical illness, which ranges from a 
nonspecifi c viral syndrome (dengue 
fever [DF]) to severe and fatal hem-
orrhagic disease (dengue hemorrhagic 
fever [DHF]). DF/DHF occurs primar-
ily in tropical and subtropical areas of 
the world. Domestic dengue virus in-
fection occurs in >100 countries; >2.5 
billion persons live in these areas. Ap-
proximately 100 million cases of DF, 
500,000 cases of DHF, and several 
thousand deaths occur annually world-
wide (1). During the past decades, 
dengue virus has emerged in south-
ern Asia; DF/DHF epidemics have 
occurred in Bhutan, India, Maldives, 
Bangladesh, and Pakistan (2–4).
From August through November 
2006, the number of febrile patients 
increased in 4 major hospitals in the 
Terai region of Nepal: Nepalgunj 
Medical College, Bheri Zonal Hospi-
tal in Nepalgunj, Tribhuban Hospital 
in Dang, and Narayani subregional 
hospital in Birgunj. Patients with se-
vere symptoms were referred to Sukr-
araj Tropical and Infectious Disease 
Hospital, Kathmandu, for diagnosis 
and treatment. The clinical features 
in most patients were consistent with 
signs of DF, but some patients showed 
signs (high fever, rash, ecchymosis, 
epistaxis, positive tourniquet test, liv-
er dysfunction, and thrombocytopenia 
[platelet count <100,000/mm3]) con-
sistent with the World Health Organi-
zation (WHO) defi nition of DHF. As-
cites and plural effusion developed in 
2 patients. Blood specimens were col-
lected from all patients at the time of 
admission to the local hospitals. Par-
ticle agglutination (PA) assay (Pentax 
Ltd, Tokyo, Japan) (5) and immuno-
globulin (Ig) M–capture ELISA (Den-
gue/JE IgM Combo ELISA kit, Panbio 
Ltd, Brisbane, Queensland, Australia) 
were performed. Dengue virus–specif-
ic IgM was detected in 11 patients who 
had fever, headache, and rash (Table). 
Each of these patients had negative 
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Table. Clinical and laboratory data for 11 patients admitted to hospitals and diagnosed with dengue fever or dengue hemorrhagic
fever, Nepal, 2006* 
Patient
age, y/Sex
Month
admitted Location
Initial
diagnosis
Travel
history
Clinical signs and 
symptoms Selected laboratory and other test results 
20/M Sep Kathmandu DF Yes Fever, headache, 
nausea
Hb 15.4 g/dL; TLC 10,500/mm3;
Plt 185,000/mm3; blood culture for 
salmonellae negative; ALT 38 IU/L 
27/F Sep Bardiya Viral fever No Fever, headache, 
vomiting
TLC 5,600/mm3; blood culture for 
salmonellae negative 
3/M Sep Salayan Encephalitis No Fever, vomiting, 
convulsions
Widal negative; TLC 4,700/mm3
13/M Oct Sindhuli Typhoid 
fever
No Fever, headache Widal negative; TLC 4,500/mm3; blood 
culture for salmonellae negative; Brucella
antigen negative; chest radiograph normal 
22/M Oct Birgunj DHF No Fever, headache, 
vomiting, ascites 
Bil 0.8 mg/dL; ALT 80 IU/L; Plt 22,000/mm3;
chest radiograph normal 
55/F Oct Dang DF No Fever, headache, 
muscular pain 
Plt 51,000/mm3; TLC 7,600/mm3; MP 
negative; ESR 20 mm/h; Bil 0.7 mg/dL 
22/F Oct Birgunj Viral fever No Fever, headache,  
body ache 
Brucella negative; Widal negative;
TLC 5,600/mm3
13/M Nov Dang DF No Fever, headache, 
rashes
Plt 95,000/mm3; TLC 4,700/mm3;
Hb 13.1 g%; Bil 0.8mg/dL; ALT 26 IU/L 
35/F Nov Birgunj DHF No Fever, headache, 
bruises; tourniquet: 
positive
Bil 0.81mg/dL; Plt 31,000/mm3;
PT 2 min 30 s (control 14) 
40/M Nov Birgunj DF No Fever, headache, 
rashes
ALT 127IU/L; Plt 110,000 /mm3;
PCV 38.8%;TLC 5,500/mm3;
ultrasonography liver size, 16.8 cm 
42/M Nov Dang DF No Fever, headache, 
rashes
Bil 0.7 mg/dL; Widal test negative;
TLC 6,800/mm3; Plt 164,000/mm3
*Blood specimens were collected at time of hospital admission. Diagnosis was confirmed by using immunoglobulin M–capture ELISA. DF, dengue fever; 
Hb, hemoglobulin;TLC, total leukocyte count; Plt, platelets; ALT, alanine aminotransferase; DHF, dengue hemorrhagic fever Bil, bilirubin; MP, malaria 
parasites; ESR, erythrocyte sedimentation rate; PT, prothrombin time; PCV, packed cell volume. 
